Tumor Biology

, Volume 35, Issue 12, pp 12601–12605 | Cite as

Clinical analysis of chronic lung injury in patients with non-Hodgkin lymphoma after CHOP chemotherapy

  • Zhenchang Sun
  • Xin Li
  • Xiaolong Wu
  • Xiaorui Fu
  • Ling Li
  • Lei Zhang
  • Yu Chang
  • Mingzhi Zhang
Research Article
  • 106 Downloads

Abstract

We conducted a preliminarily study on the clinical characteristics of chronic lung injury (CLI) in patients with non-Hodgkin lymphoma (NHL) after CHOP chemotherapy and observed the effects of this injury on CHOP treatment efficacy. Sixty patients who were diagnosed as NHL and received CHOP chemotherapy in hospital were enrolled for this clinical trial. CLI was assessed by clinical symptoms and computed tomography (CT) scan conducted before and after chemotherapy. The effect of CLI on the efficacy of CHOP chemotherapy in patients with NHL was evaluated by comparing treatment response and recurrence rate to patients with no signs of lung injury. Our CT scans revealed multiple signs of CLI in 35 patients (56.67 %), such as pulmonary diffuse, limited infiltration shadow or ground glass-like changes. Among them, 23 patients (38.33 %) showed bilateral diffuse lung injury and 12 (20.00 %) showed topical lung injury. Most patients suffering from 6 to 12 months delayed recurrence exhibited signs of CLI. The inflammatory response of CLI may increase the risk of disease progression and recurrence. Therefore, early diagnosis and intervention, which play a positive role in the clinical treatment and the long-term efficacy, are critical for patients with NHL.

Keywords

Lymphoma CHOP Lung injury after chemotherapy 

References

  1. 1.
    Massin F, Fur A, Reybet-Degat O, Camus P, Jeannin L. Busulfan-induced pneumopathy. Rev Mal Respir. 1987;4:3–10.PubMedGoogle Scholar
  2. 2.
    Sun Y, Shi YK. Manual of medical oncology. People’s Medical Publishing House, 2012: 378.Google Scholar
  3. 3.
    Vargas HA, Hampson FA, Babar JL, et al. Imaging the lungs in patients treated for lymphoma. Clin Radiol. 2009;64(11):1048–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Affara NI, Coussens LM. IKKalpha at the crossroads of inflammation and metastasis. Cell. 2007;129:25–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Sakai F, Johkoh T, Kusumoto M, Arakawa H, Takahashi M. Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings. Int J Clin Oncol. 2012;17:542–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002;57:292–9.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Zhenchang Sun
    • 1
  • Xin Li
    • 1
  • Xiaolong Wu
    • 1
  • Xiaorui Fu
    • 1
  • Ling Li
    • 1
  • Lei Zhang
    • 1
  • Yu Chang
    • 1
  • Mingzhi Zhang
    • 1
  1. 1.Department of Medical OncologyFirst Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

Personalised recommendations